Hetero launches generic semaglutide portfolio in overseas markets
Hetero launches its generic semaglutide portfolio in international markets, enhancing access to advanced diabetes and obesity therapies.
Hetero launches its generic semaglutide portfolio in international markets, enhancing access to advanced diabetes and obesity therapies.
What's Your Reaction?
DDP Editor
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
